Cargando…

Cannabinoid signaling and risk in Huntington's disease

Dysregulated endocannabinoid (eCB) signaling and the loss of cannabinoid receptors (CB1Rs) are important phenotypes of Huntington's disease (HD) but the precise contribution that eCB signaling has at the circuit level is unknown. Using a computational model of spiking neurons, synapses, and eCB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Humble, James, Kozloski, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479462/ https://www.ncbi.nlm.nih.gov/pubmed/36118134 http://dx.doi.org/10.3389/fncom.2022.903947

Ejemplares similares

Striatal Network Models of Huntington's Disease Dysfunction Phenotypes
por: Zheng, Pengsheng, et al.
Publicado: (2017)

Cortico-Striatal Cross-Frequency Coupling and Gamma Genesis Disruptions in Huntington’s Disease Mouse and Computational Models
por: Naze, Sebastien, et al.
Publicado: (2018)

Huntington’s Disease and Striatal Signaling
por: Roze, Emmanuel, et al.
Publicado: (2011)

Striatal network modeling in Huntington’s Disease
por: Ponzi, Adam, et al.
Publicado: (2020)

Closed-Loop Brain Model of Neocortical Information-Based Exchange
por: Kozloski, James
Publicado: (2016)

Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington’s Disease Mice
por: Holley, Sandra M., et al.
Publicado: (2019)

Purinergic Signaling in the Pathophysiology and Treatment of Huntington’s Disease
por: Wiprich, Melissa Talita, et al.
Publicado: (2021)

An Ultrascalable Solution to Large-scale Neural Tissue Simulation
por: Kozloski, James, et al.
Publicado: (2011)

Impaired Redox Signaling in Huntington’s Disease: Therapeutic Implications
por: Paul, Bindu D., et al.
Publicado: (2019)

A Theory of Loop Formation and Elimination by Spike Timing-Dependent Plasticity
por: Kozloski, James, et al.
Publicado: (2010)

Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease
por: Kendall, Debra A., et al.
Publicado: (2017)

Risk-taking and pathological gambling behavior in Huntington’s disease
por: Kalkhoven, Carla, et al.
Publicado: (2014)

Altered Intracortical T(1)-Weighted/T(2)-Weighted Ratio Signal in Huntington’s Disease
por: Rowley, Christopher D., et al.
Publicado: (2018)

Self-referential forces are sufficient to explain different dendritic morphologies
por: Memelli, Heraldo, et al.
Publicado: (2013)

Acanthocytes Identified in Huntington’s Disease
por: Yu, Yueyi, et al.
Publicado: (2022)

Contribution of Neuroepigenetics to Huntington’s Disease
por: Francelle, Laetitia, et al.
Publicado: (2017)

Refining the diagnosis of Huntington disease: the PREDICT-HD study
por: Biglan, Kevin M., et al.
Publicado: (2013)

Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling
por: Laprairie, Robert B., et al.
Publicado: (2019)

Cannabinoid Signaling in Auditory Function and Development
por: Ghosh, Sumana, et al.
Publicado: (2021)

Altered Cholesterol Homeostasis in Huntington’s Disease
por: Kacher, Radhia, et al.
Publicado: (2022)

Commentary: Acanthocytes identified in Huntington's disease
por: Peikert, Kevin, et al.
Publicado: (2022)

Corticostriatal Dysfunction in Huntington’s Disease: The Basics
por: Bunner, Kendra D., et al.
Publicado: (2016)

Microglial Activation in the Pathogenesis of Huntington’s Disease
por: Yang, Hui-Ming, et al.
Publicado: (2017)

Cortical and Striatal Circuits in Huntington’s Disease
por: Blumenstock, Sonja, et al.
Publicado: (2020)

The Role of Microglia and Astrocytes in Huntington’s Disease
por: Palpagama, Thulani H., et al.
Publicado: (2019)

Excessive response to provocation rather than disinhibition mediates irritable behaviour in Huntington’s disease
por: McLauchlan, Duncan James, et al.
Publicado: (2022)

Early dysfunction and progressive degeneration of the subthalamic nucleus in mouse models of Huntington's disease
por: Atherton, Jeremy F, et al.
Publicado: (2016)

Enhanced GABAergic Inhibition of Cholinergic Interneurons in the zQ175(+/−) Mouse Model of Huntington's Disease
por: Lim, Sean Austin O., et al.
Publicado: (2021)

Role of cerebral cortex in the neuropathology of Huntington's disease
por: Estrada-Sánchez, Ana M., et al.
Publicado: (2013)

Motor–Language Coupling in Huntington’s Disease Families
por: Kargieman, Lucila, et al.
Publicado: (2014)

Ubiquitin–proteasome system involvement in Huntington’s disease
por: Ortega, Zaira, et al.
Publicado: (2014)

Multiple Aspects of Gene Dysregulation in Huntington’s Disease
por: Moumné, Lara, et al.
Publicado: (2013)

Huntingtin Aggregates in the Olfactory Bulb in Huntington’s Disease
por: Highet, Blake, et al.
Publicado: (2020)

Pain in Huntington’s disease and its potential mechanisms
por: Li, Jiajie, et al.
Publicado: (2023)

Editorial: Cannabinoids as potential treatment for neurological diseases
por: Gómez-Cañas, María, et al.
Publicado: (2022)

Huntington's disease: of mice and men
por: Yhnel, Emma
Publicado: (2017)

Cholinergic Interneurons Amplify Corticostriatal Synaptic Responses in the Q175 Model of Huntington’s Disease
por: Tanimura, Asami, et al.
Publicado: (2016)

Modulation of Human Peripheral Blood Mononuclear Cell Signaling by Medicinal Cannabinoids
por: Utomo, Wesley K., et al.
Publicado: (2017)

Cannabinoids Modulate Light Signaling in ON-Sustained Retinal Ganglion Cells of the Mouse
por: Middleton, Terence Peter, et al.
Publicado: (2019)

Striatal Chloride Dysregulation and Impaired GABAergic Signaling Due to Cation-Chloride Cotransporter Dysfunction in Huntington’s Disease
por: Serranilla, Melissa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kubrrfp7hj7kpkg0knsca5btbq